Inhibitors of janus kinases and infection in patients of rheumatologic profile

In recent decades, there has been clear progress in rheumatology associated with the introduction of genetically engineered biological drugs, as well as targeted basic anti-inflammatory drugs (tBPVP), which include Janus kinase inhibitors. At the same time, the use of these drugs is associated with an increasing risk of developing infections of various nature and localization, as well as reactivation of latent infection. In addition, cases of severe infections, including fatal ones, are registered. This review analyzes the literature data, mainly from the last 5 years, concerning the frequency and localization of major comorbid infections in patients with rheumatoid arthritis and psoriatic arthritis in the treatment of various tBPVS (tofacitinib, baricitinib, upadacitinib). The significance of infections (tuberculosis, herpes-viral infections, chronic viral hepatitis B) in the management of these patients is characterized. The need for a wider use of various vaccines (primarily anti-pneumococcal and anti-influenza) in patients with immuno-inflammatory rheumatic diseases is emphasized.